Pappas-Gogos George, Tepelenis Kostas, Fousekis Fotis, Katsanos Konstantinos, Pitiakoudis Michail, Vlachos Konstantinos
Department of Surgery, University Hospital of Ioannina, 45500 Ioannina, Greece.
Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece.
Cancers (Basel). 2022 Apr 18;14(8):2039. doi: 10.3390/cancers14082039.
Gastric cancer (GC) is one of the most common and deadly malignancies worldwide. Helicobacter pylori have been documented as a risk factor for GC. The development of sequencing technology has broadened the knowledge of the gastric microbiome, which is essential in maintaining homeostasis. Recent studies have demonstrated the involvement of the gastric microbiome in the development of GC. Therefore, the elucidation of the mechanism by which the gastric microbiome contributes to the development and progression of GC may improve GC's prevention, diagnosis, and treatment. In this review, we discuss the current knowledge about changes in gastric microbial composition in GC patients, their role in carcinogenesis, the possible therapeutic role of the gastric microbiome, and its implications for current GC therapy.
胃癌(GC)是全球最常见且致命的恶性肿瘤之一。幽门螺杆菌已被证明是胃癌的一个风险因素。测序技术的发展拓宽了我们对胃微生物群的认识,胃微生物群对于维持体内平衡至关重要。最近的研究表明胃微生物群参与了胃癌的发生发展。因此,阐明胃微生物群促进胃癌发生发展的机制可能会改善胃癌的预防、诊断和治疗。在本综述中,我们讨论了目前关于胃癌患者胃微生物组成变化的知识、它们在致癌过程中的作用、胃微生物群可能的治疗作用及其对当前胃癌治疗的影响。